title: A phase II study of combined chemoradiotherapy for limited disease-small-cell lung cancer.
abstract: A study to evaluate the efficacy of cisplatin, doxorubicin, and etoposide chemotherapy with combined radiotherapy was undertaken in 26 patients with limited disease-small-cell lung cancer. Patients were treated with cisplatin (80 mg/m2) intravenously (i.v.) on day 1, doxorubicin (30 mg/m2) i.v. on day 1, and etoposide (80 mg/m2) i.v. on days 1, 3, and 5, every 4 weeks for four cycles. Thoracic irradiation of 40 Gy in 20 fractions was delivered during 4 weeks to the primary site starting on day 8 of the second cycle of chemotherapy. The objective response rate was 100%. A complete response was observed in 10 patients (38%). The median survival time was 23 months, and the 3-year survival rate was 42%. Seven patients (27%) continued to survive at least 8 years and remain free from disease. Grade III/IV leukopenia was observed in 25 patients (96%). Grade III/IV thrombocytopenia developed in 19 patients (73%). Grade III/IV esophagitis was not seen. Interstitial pneumonitis occurred in two patients. This regimen is effective and has acceptable toxicity for use in the treatment of limited disease-small-cell lung cancer.
authors.affiliation: Department of Internal Medicine, National Nishi-Gunma Hospital, Shibukawa, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Ishihara
authors.forename: S
authors.initials: S
authors.lastname: Tsuchiya
authors.forename: K
authors.initials: K
authors.lastname: Minato
authors.forename: S
authors.initials: S
authors.lastname: Watanabe
authors.forename: N
authors.initials: N
authors.lastname: Sunaga
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: G
authors.initials: G
authors.lastname: Kobayashi
authors.forename: H
authors.initials: H
authors.lastname: Hoshino
authors.forename: I
authors.initials: I
authors.lastname: Naruse
authors.forename: T
authors.initials: T
authors.lastname: Makimoto
authors.forename: T
authors.initials: T
authors.lastname: Nomoto
authors.forename: Y
authors.initials: Y
authors.lastname: Takei
authors.forename: N
authors.initials: N
authors.lastname: Fueki
authors.forename: A
authors.initials: A
authors.lastname: Takise
authors.forename: R
authors.initials: R
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Mori
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004941:Esophagitis / Q000139:chemically induced; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin